Incyte Corp (NASDAQ:INCY)

graph

5 Biotechs With the Most Upside This Earnings Cycle

With earnings just around the corner, one key analyst is taking the opportunity to share its thoughts on select mid-cap and large-cap biotech companies. Despite a modest erosion to fundamentals and sector ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
buy sell stocks

Top Analyst Upgrades and Downgrades: Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration, Nike and More

Stocks were looking for direction on Wednesday. With the S&P 500 and Dow going positive for the year just at the end of last week, investors now have to wonder ...
Read Full Story »
buy button

Massive Biotech Purchases Highlight Insider Buying: Incyte, TransDigm, Prospect Capital, Xenoport and More

Finally, after what seemed like the longest six weeks in history, the market staged at least a solid attempt to rally and restore investor confidence this past week. Firming oil ...
Read Full Story »
biotech word cloud

4 BioPharma Movers That Cannot Be Ignored

Over the past week, a few biotech companies made absolutely massive runs, either up and down. In the past year, the health care sector was on fire from positive trials, ...
Read Full Story »
coins

Incyte Underwhelms With Earnings

Incyte Corp. (NASDAQ: INCY) reported its fourth-quarter financial results after the markets closed on Wednesday. The company had $0.29 in earnings per share (EPS) on $243.88 million in revenue, which ...
Read Full Story »
graph

Despite Target Cuts, Analysts Stick With Incyte for Big Upside

Incyte Corp. (NASDAQ: INCY) took it on the chin this past week following the announcement that its Phase 2 trial of ruxolitinib would be stopped. This was detrimental to the ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal, Qualcomm, US Steel and More

Stocks were indicated slightly higher on Thursday after a dovish Federal Reserve decision on rates did not keep selling pressure away on Wednesday. Investors may have seen every rally of ...
Read Full Story »
biotech word cloud

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. There is a challenging macro setup, but headwinds combined with a relatively attractive valuation could carry ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: AMD, Amazon, Celgene, Comerica, Fortinet, Gilead, Lennar, Netflix, Voya, Wayfair and Many More

Stocks were getting bruised on Wednesday with overseas pressure and oil sending Dow (-250) and S&P (-29) futures down yet again. Investors have to be thinking that 2016 is becoming ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Stocks were pounded lower yet again on Wednesday, but this time on fears of a North Korean hydrogen bomb test. The stock market is off to a rocky start in ...
Read Full Story »
biotech word cloud

Hot Biotech Stocks Highlight Jefferies Top Growth Stocks to Buy This Week

Despite a very difficult week for investors, more data came in to support the huge jobs number at the beginning of the month. The NFIB Small Business Optimism Index held ...
Read Full Story »
Test tubes

Big Biotech Is Cheap With Strong Cash Flows: 3 to Buy Before Earnings

The political candidates were at it again during the recent Democratic Party debate. Evil pharmaceutical and biotech companies are charging too much. The fact of the matter is every four ...
Read Full Story »
generic drugs

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

Since the peak of the biotech index in late July, the industry has dropped a staggering 24% through the end of the third quarter, versus the 10% drop in the ...
Read Full Story »
buy sell

Jefferies Starts Coverage on Biotechs: 3 Top Stocks to Buy Now

Despite the tremendous run the biotech sector has had over the past five years, many of the top stocks, especially the large cap leaders, trade at multiples that mimic low-growth ...
Read Full Story »